Asset profile
EVO101
Small molecule
Evidence outlook · lead readout
NCT05579899 · Atopic Dermatitis Eczema
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05579899: The study was randomized, triple-blinded, vehicle-controlled, and included 119 participants, with the clinical EASI measure as its primary endpoint. The primary comparison is unclear because the reported mean change favored vehicle cream (-62.0% versus -43.5% with EVO101) but no p-value or confidence interval is provided.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.